US2008020979A1PendingUtilityA1

Peptides of Syndecan-1 For Inhibiting Angiogenesis

58
Individually held — no corporate assignee on recordPriority: Jun 9, 2006Filed: Jun 8, 2007Published: Jan 24, 2008
Est. expiryJun 9, 2026(expired)· nominal 20-yr term from priority
Inventors:Alan RapraegerDeannalee M. Beauvais
C07K 14/4725A61K 45/06A61K 38/1709A61K 38/00C07K 7/06A61P 43/00C07K 7/08C07K 14/705
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides a peptide derived from the extracellular domain of syndecan-1 that inhibits angiogenesis.

Claims

exact text as granted — not AI-modified
1 . An isolated and purified peptide or polypeptide segment consisting of between 5 and 100 amino acid residues and comprising SEQ ID NO:21 or SEQ ID NO:13, wherein the segment is not SEQ ID NO:28.  
     
     
         2 . The isolated and purified peptide or polypeptide of  claim 1 , wherein said peptide or polypeptide is 10, 15, 20, 25, 30, 35, 40, 45, 49, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 amino acid residues in length.  
     
     
         3 . The isolated and purified peptide or polypeptide of  claim 1 , wherein said peptide or polypeptide is between 10 and 80 amino acid residues in length.  
     
     
         4 . The isolated and purified peptide or polypeptide of  claim 1 , wherein said peptide or polypeptide is between 20 and 50 amino acid residues in length.  
     
     
         5 . The isolated and purified peptide or polypeptide of  claim 1 , wherein said peptide or polypeptide is between 30 and 40 amino acid residues in length.  
     
     
         6 . The isolated and purified peptide of  claim 1 , wherein said peptide consists of SEQ ID NO:10.  
     
     
         7 . The isolated and purified peptide of  claim 1 , wherein said peptide comprises at least 35 contiguous amino acids from SEQ ID NO:10.  
     
     
         8 . The isolated and purified peptide of  claim 1 , wherein said peptide consists of SEQ ID NO:28.  
     
     
         9 . The isolated and purified peptide of  claim 1 , wherein said peptide consists of SEQ ID NO:21.  
     
     
         10 . A nucleic acid encoding a peptide or polypeptide segment consisting of between 5 and 100 amino acid residues and comprising SEQ ID NO:21 or SEQ ID NO:13, wherein the segment is not SEQ ID NO:28.  
     
     
         11 - 19 . (canceled)  
     
     
         20 . The isolated and purified peptide of  claim 1 , dispersed in a pharmaceutically acceptable buffer or diluent.  
     
     
         21 . A method of inhibiting interaction of α v β 3  or α v β 5  integrin with syndecan-1 comprising contacting a α v β 3  or α v β 5  integrin molecule with a peptide or polypeptide segment consisting of between 5 and 100 amino acid residues and comprising SEQ ID NO:21 or SEQ ID NO:13, wherein the segment is not SEQ ID NO:28.  
     
     
         22 . The method of  claim 21 , wherein said peptide or polypeptide is 10, 15, 20, 25, 30, 35, 40, 45, 49, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 amino acid residues in length.  
     
     
         23 . The method of  claim 21 , wherein said peptide or polypeptide is between 10 and 80 amino acid residues in length.  
     
     
         24 . The method of  claim 21 , wherein said peptide or polypeptide is between 20 and 50 amino acid residues in length.  
     
     
         25 . The method of  claim 21 , wherein said peptide or polypeptide is between 30 and 40 amino acid residues in length.  
     
     
         26 . The method of  claim 21 , wherein said peptide consists of SEQ ID NO:10.  
     
     
         27 . The method of  claim 21 , wherein said peptide comprises at least 35 contiguous amino acids from SEQ ID NO:10.  
     
     
         28 . The method of  claim 21 , wherein said peptide consists of SEQ ID NO:28.  
     
     
         29 . The method of  claim 21 , wherein said peptide consists of SEQ ID NO:21.  
     
     
         30 . The method of  claim 21 , wherein said α v β 3  or α v β 5  integrin is located on the surface of a cell.  
     
     
         31 . The method of  claim 30 , wherein said cell is a cancer cell.  
     
     
         32 . The method of  claim 31 , wherein said cancer cell is a carcinoma, a myeloma, a melanoma or a glioma.  
     
     
         33 . The method of  claim 31 , further comprising contacting said cancer cell with a second cancer inhibitory agent.  
     
     
         34 . The method of  claim 31 , wherein said cancer cell is a metastatic cancer cell.  
     
     
         35 . A method of inhibiting α v β 3  or α v β 5  integrin activation by syndecan-1 comprising contacting a cell expressing an α v β 3  or α v β 5  integrin molecule with a peptide or polypeptide segment consisting of between 5 and 100 amino acid residues and comprising SEQ ID NO:21 or SEQ ID NO:13, wherein the segment is not SEQ ID NO:28.  
     
     
         36 - 44 . (canceled)  
     
     
         45 . A method of treating a subject with a cancer, cells of which express α v β 3  or α v β 5  integrin, comprising contacting said cells with a peptide or polypeptide segment consisting of between 5 and 100 amino acid residues and comprising SEQ ID NO:21 or SEQ ID NO:13, wherein the segment is not SEQ ID NO:28.  
     
     
         46 . The method of  claim 45 , wherein said peptide or polypeptide is 10, 15, 20, 25, 30, 35, 40, 45, 49, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 amino acid residues in length.  
     
     
         47 . The method of  claim 45 , wherein said peptide or polypeptide is between 10 and 80 amino acid residues in length.  
     
     
         48 . The method of  claim 45 , wherein said peptide or polypeptide is between 20 and 50 amino acid residues in length.  
     
     
         49 . The method of  claim 45 , wherein said peptide or polypeptide is between 30 and 40 amino acid residues in length.  
     
     
         50 . The method of  claim 45 , wherein said peptide consists of SEQ ID NO:10.  
     
     
         51 . The method of  claim 45 , wherein said peptide comprises at least 35 contiguous amino acids from SEQ ID NO:10.  
     
     
         52 . The method of  claim 45 , wherein said peptide consists of SEQ ID NO:28.  
     
     
         53 . The method of  claim 45 , wherein said peptide consists of SEQ ID NO:21.  
     
     
         54 . The method of  claim 45 , wherein said subject is a human.  
     
     
         55 . The method of  claim 45 , wherein said cancer is a carcinoma, a myeloma, a melanoma or a glioma.  
     
     
         56 . The method of  claim 45 , wherein said peptide or polypeptide is administered directly to said cancer cells, local to said cancer cells, regional to said cancer cells, or systemically.  
     
     
         57 . The method of  claim 45 , further comprising administering to said subject a second cancer therapy selected from chemotherapy, radiotherapy, immunotherapy, hormonal therapy, or gene therapy.  
     
     
         58 . A method of inhibiting angiogenesis comprising contacting an endothelial cell expressing an α v β 3  or α v β 5  integrin molecule with a peptide or polypeptide segment consisting of between 5 and 100 amino acid residues and comprising SEQ ID NO:21 or SEQ ID NO:13.  
     
     
         59 - 65 . (canceled)  
     
     
         66 . The method of  claim 58 , wherein said peptide consists of SEQ ID NO:21.  
     
     
         67 . A method of treating a subject having a disease characterized by angiogenesis comprising contacting endothelial cells which express α v β 3  or α v β 5  integrin and are responsible for said angiogenesis, with a peptide or polypeptide segment consisting of between 5 and 100 amino acid residues and comprising SEQ ID NO:21 or SEQ ID NO:13, wherein the disease is not cancer.  
     
     
         68 - 75 . (canceled)  
     
     
         76 . The method of  claim 67 , wherein said disease is an abnormality of the vasculature (atherosclerosis and hemangiomas), of the eye (diabetic retinopathy and retinopathy of prematurity), of the skin (pyogenic granulomas, psoriasis, warts, scar keloids, allergic edema, ulcers), of the uterus and ovary (dysfunctional uterine bleeding, follicular cysts, endometriosis, pre-eclampsia), of the adipose tissue (obesity), of the bones and joints (rheumatoid arthritis, osteophyte formation), and AIDS-related pathologies resulting from TAT protein of the human immunodeficiency virus (HIV) activating the avb3 integrin on endothelial cells.  
     
     
         77 - 80 . (canceled)

Join the waitlist — get patent alerts

Track US2008020979A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.